Immunomedics, Inc.

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Other

Gary L Griffiths

Hans J Hansen

David M Goldenberg

William John McBride

Serengulam V Govindan

Zhengxing Qu

Shui-on Leung

Habibe Karacay

Peter Choyke

Haitao Wu

Noriko Sato

Anastasia Lentine-Jones

Bo B Lundberg

Seregulam V Govindan

Jay R Knutson

Ruth Grebenau

Jerry Shevitz

Habibe Diril

Hans L Hansen

Michelle Losman

William J Mcbride

Shui-On Leung

The invention provides a method of preparing aZr-oxine complex of the formula The invention also provides a method of labeling a cell with theZr-oxine complex and a method for detecting a biological cell in a subject comprising administering theZr-oxine complex to the subject.

Method of preparing zirconium-89 oxine complex

Zirconium-89 oxine complex as a cell labeling agent for positron emission tomography

The invention provides a method of preparing aZr-oxine complex of the formula. The invention also provides a method of labeling a cell with theZr-oxine complex and a method for detecting a biological cell in a subject comprising administering theZr-oxine complex to the subject. 

Composite probes for super resolution optical techniques using super resolution via transiently activated quenchers (STAQ) include a donor moiety and an acceptor moiety joined by a linker, wherein the acceptor moiety, when excited by incident radiation, is excited to a state which, for example, absorbs in the donor emission region, such that the acceptor moiety in its excited state quenches at least a portion of the donor moiety emission. Other transiently activated quenching mechanisms and moieties could accomplish the same task by reducing donor population. Also disclosed are methods for irradiating a selected region of a target material including the composite probe, wherein the composite probe enables improved resolution by point spread function modification and/or nanoscale chemical reactions.

Composite probes and use thereof in super resolution methods

The invention relates to therapeutic conjugates with the ability to target various antigens. The conjugates contain a targeting antibody or antigen binding fragment thereof and an anthracycline chemotherapeutic drug. The targeting antibody and the chemotherapeutic drug are linked via a linker comprising a hydrazide moiety.

Anthracycline-antibody conjugates for cancer therapy

Disclosed are compositions that include anti-CD74 immunoconjugates and a therapeutic and/or diagnostic agent. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. The compositions may be part of a kit for administering the anti-CD74 immunoconjugate compositions in therapeutic and/or diagnostic methods.

Anti-CD74 immunoconjugates and methods

Anthracycline-Antibody Conjugates for Cancer Therapy

The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them.

Production and use of novel peptide-based agents for use with bi-specific antibodies

The present invention is directed to methods for treating cancer wherein more than one therapeutic agent is used, with each of the therapeutic agents having different tumor-killing capabilities, and wherein the therapeutic agents are delivered to the tumor sites using combined targeting and pre-targeting methods. The methods of the present invention achieve good tumor to non-tumor ratios of the therapeutic agents, and are effective for cancer therapy.

Targeted combination immunotherapy of cancer and infectious diseases

Embodiments of the invention relate to a method for treating target cells, tissues or pathogens in a subject, comprising administering a non-covalently bound complex which comprises a multispecific targeting protein and a hapten-enzyme covalent conjugate, followed by administration of a prodrug that is converted to an active drug by the enzyme. Other embodiments of the invention further relate to kits comprising the non-covalently bound complex or the components to prepare the complex.

Use of multispecific, non-covalent complexes for targeted delivery of therapeutics

Disclosed are compositions that include anti-CD74 immunoconjugates and a therapeutic and/or diagnostic agent. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. The compositions may be part of a kit for administering the anti-CD74 immunoconjugates compositions in therapeutic and/or diagnostic methods.

Growing community of inventors

Morristown, NJ, United States of America

Gary L Griffiths